567 Customer Publications Validate Absin mIHC Kit: A Reliable Choice for High‑Impact Manuscripts

For studies on tumor microenvironment and spatial immune in‑situ profiling, multiplexed immunohistochemistry (mIHC) has become an indispensable core technique. Nevertheless, many researchers encounter difficulties in kit selection: products with appealing advertised specifications often suffer from high staining background, weak signal intensity and substantial batch‑to‑batch variation in practical experiments. Failed assays waste precious tissue specimens and delay manuscript preparation.

The most rigorous criterion for evaluating an mIHC kit lies in the quantity and quality of peer‑reviewed publications generated by real‑world end‑users.

As one of the early domestic brands dedicated to TSA‑mIHC technology, Absin has accumulated long‑term technical expertise. Thanks to its consistent staining performance, Absin kits have gained recognition from numerous research teams across China. As of September 2026, de‑duplicated public papers citing Absin mIHC kits have reached 567.

According to a third‑party industrial statistical report from Zhiliaowo, Absin ranks among the leading domestic suppliers of TSA‑mIHC kits in terms of publication output. The report also reveals key trends within the industry:

• Rapid market expansion: The number of domestic publications involving TSA kits rose from 62 in 2020 to 615 in 2025. A total of 428 papers were indexed in the first seven months of 2026. The TSA technique has transitioned from widespread adoption to a second round of accelerated growth, and the domestic market remains on a robust upward trajectory.
• Market share reversal for domestic brands: Imported brands once held 85.51 % of the market share in 2020. Local brands achieved a historic turnaround in 2022. As of July 2026, domestic manufacturers have captured 83.07 % of the market, driven by cost‑effective products and localized technical support.
• Restructured competitive landscape: The previous monopoly by a single supplier has ended, ushering in a multi‑polarized competitive phase with fast‑growing domestic manufacturers.

Note: Industry data and conclusions are sourced from the Zhiliaowo industrial analytical report. Original link: https://mp.weixin.qq.com/s/FZlDqPxbVH5FRBPX7XqS1w

Surging Publication Output of Absin TSA‑mIHC Kits: Growing Market Acceptance

Publication statistics from end‑users clearly demonstrate the market momentum of Absin mIHC products.

Within merely five years, annual customer publications have soared from 3 to 164, representing a 55‑fold increase. A productivity boom has been observed since 2023, with annual outputs maintaining above 150 papers. For the first nine months of 2026 alone, 81 cited publications have been curated, reflecting persistent strong growth. An increasing number of research groups have adopted Absin mIHC kits as a routine laboratory tool for spatial‑pathology investigations.

Outstanding Publication Quality alongside High Volume

Beyond publication quantity, high‑impact papers constitute solid real‑world validation for Absin mIHC kits. Among the 567 customer publications:

• Maximum impact factor: 81.2 (Signal Transduction and Targeted Therapy)
• Mean impact factor of all publications: > 10
• 153 papers with IF > 10 (27 % of total); 29 papers with IF > 20; 10 papers with IF > 30

Customer‑generated results using Absin mIHC kits have appeared in top‑tier journals including Cell, Cancer Cell, Journal of Hematology & Oncology, Cell Discovery, Nature Materials, Molecular Cancer and Cancer Discovery. Leading research groups in diverse disciplines such as tumor immunology, gastroenterology, neuroscience, reproductive biology and metabolism employ Absin kits for multi‑colour co‑localization staining to generate critical in‑situ spatial evidence for manuscripts.

These high‑profile achievements confirm that Absin mIHC kits produce multiplex immunofluorescence images meeting the rigorous standards of peer reviewers for high‑calibre journals.

Why Do an Increasing Number of Research Groups Choose Absin mIHC?

• TSA signal‑amplification technology: compatible with both paraffin‑embedded and frozen tissue sections. Clear signals are obtained even for low‑abundance antigens, with well‑balanced multi‑channel signals and low background; acquired images are suitable for direct manuscript presentation.
• Comprehensive kit portfolio: a complete catalogue covering up to 230 colour combinations. Universal secondary antibodies for rabbit and mouse primary antibodies relieve constraints from host‑species matching, facilitating flexible experimental design and lowering technical barriers for novice operators.
• Large repository of validated customer publications: 567 publicly accessible references are available for reference. Researchers may refer to marker panels and staining protocols reported by peers in related research fields to mitigate experimental pitfalls.
• Professional technical support team: consulting on experimental design, troubleshooting of staining artefacts and prompt technical assistance are provided throughout workflows.

Publications speak for reagent performance. The 567 cited papers are not mere marketing claims but outcomes validated by repeated laboratory work from researchers nationwide. If you are investigating tumour microenvironment, spatial crosstalk among immune cells or in‑situ protein co‑localization in tissues, consider the extensively validated Absin multiplexed immunohistochemistry kits to convert precious tissue specimens into high‑quality research data.

Beyond mIHC kits, Absin offers an extensive portfolio of life‑science reagents. Overall citations for all Absin products exceed 21 000, encompassing antibodies, assay kits, small‑molecule compounds, Matrigel equivalents, biochemical reagents and cell‑culture supplies to support research in oncology, immunology, metabolism, neuroscience and other disciplines.

Remark: Statistics are updated to September 2026, covering publications with explicit statements of Absin mIHC kit usage.

Absin Scholarship Program: Cash or gift‑card rewards up to CNY 2000

Corresponding first authors are eligible for rewards upon publishing papers using designated Absin products with proper citation.

Reward Criteria

Base rewards are tiered by article impact factor and number of product catalog numbers cited.

Impact Factor (IF)	1‑3 catalog numbers (base reward)	4‑10 catalog numbers (base reward × 1.5)	> 10 catalog numbers (base reward × 3)
IF ＜ 1	Custom‑made figurine × 1	Custom‑made figurine × 3	Custom‑made figurine × 5
1 ≤ IF ＜ 10	CNY 100	CNY 150	CNY 300
10 ≤ IF ＜ 20	CNY 200	CNY 300	CNY 600
IF ＞ 20	CNY 500	CNY 750	CNY 1500

Additional bonus for special‑category products: Extra monetary reward superimposed on base reward applies to papers utilizing mIHC kits, mRNA‑related kits, organoid culture media/kits, Matrigel‑like matrix, multiplex‑detection kits, tissue‑dissociation kits, residue‑detection kits, glycan‑analysis kits, Co‑IP kits and ChIP kits. Eligible products are listed on the official website.

Program Specifications

• Applicants must be the first author of the published article and provide student ID or valid identification documentation.
• Publications should explicitly state that reagents were purchased from Absin / Absin (Shanghai), alongside corresponding catalog numbers.
• This incentive program takes effect on May 1, 2026 and remains valid long‑term, superseding prior reward policies. Applications for each paper must be submitted within 3 months following formal online publication.

Application Procedure

Submit your application by posting a comment under the target product page on the Absin official website and clicking “Claim reward for published paper” / “Apply for publication reward” to fill in required information. Reviews will be completed within 3 working days. Approved applicants will receive notification via email.

We appreciate the trust and support from the global research community. Let us advance together to unlock new frontiers in scientific exploration.